Arcturus combines strong liquidity, low financial leverage, and a sizable cash reserve with a proprietary, clinically validated mRNA technology stack, focused rare‑disease and vaccine programs, and partnerships that help de‑risk development and manufacturing while offering potential upside if key assets succeed.

Major risks include persistent operating and cash flow losses, dependence on external funding over time, significant clinical and regulatory uncertainty around its small number of lead programs, stiff competition from larger mRNA and gene‑therapy peers, and the possibility that accounting‑driven net profit in the latest year may mask ongoing underlying economic losses.

The forward picture is that of a high‑risk, high‑potential clinical‑stage biotech: if pivotal trials in rare diseases and infectious diseases deliver strong, differentiated data, Arcturus’s technology and balance sheet give it room to scale; if results disappoint or timelines slip, ongoing cash burn and competitive pressure could erode its current advantages, making execution over the next few years particularly critical.